Abbott to Separate into Two Leading Companies in Diversified Medical Products and Research-Based Pharmaceuticals
mehr
- Sprache:
-
Medien:
Alle
- Zeitraum:
- Zeitraum:Gesamt
Abbott Confirms Long-Term Commitment to HIV Care with the Planned Development of New Formulations
mehrAbbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech
mehrTwenty-Five Years of HIV Blood Testing Helped to Positively Transform Global Health Crisis
mehrAbbott Completes Acquisition of Solvay Pharmaceuticals
mehrAbbott to Suspend Marketing of Obesity Medicine Sibutramine in European Union Countries
mehrAbbott Receives European Regulatory Approval for New Ovarian Cancer Diagnostic Test
mehrNew Abbott Gene-Based Test for Colorectal Cancer Receives CE Mark
mehrAbbott Announces Positive Three-Year Data on Its Fully Bioabsorbable Stent Technology, Initiates Large-Scale International Trial
mehr
Abbott to Acquire Solvay Pharmaceuticals Business
mehrResults from Abbott's PROSPECT Study Provide New Insight into Role of Vulnerable Plaque in Coronary Artery Disease
mehrAbbott's XIENCE V(R) Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS(R) Liberte in Investigator-Initiated COMPARE Trial
mehrAbbott's XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial
mehrAbbott's XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
mehrAbbott Launches Next-Generation XIENCE PRIME(TM) Drug Eluting Stent in International Markets
mehrAbbott Receives CE Mark for Company's Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Advancing Leadership Position
mehrAbbott Recognized on Dow Jones Sustainability Index (DJSI) for Fourth Consecutive Year
mehrAbbott Study Shows Investigational Heat-Stable Norvir(R) Tablet Provides Similar Drug Levels to Current Norvir Capsule
mehr
Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines
mehrAbbott Fund and the Government of Tanzania Celebrate Milestone in Strengthening Nation's Health Care System
mehrFDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent
mehrNew Abbott Aluvia(R) Tablet for Treatment of HIV Available in South Africa
mehrAbbott Launches Next-Generation StarClose(R) SE Vascular Closure System
mehrXIENCE(TM) V Drug Eluting Stent from Abbott Reduces Major Adverse Cardiac Events in Small Vessel Patients Out to One Year
mehrXIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
mehrNew Abbott Kaletra(R) (lopinavir/ritonavir) Lower-Strength Tablet for Pediatric Use Approved in Europe
mehrAbbott Gains Reimbursement for XIENCE(TM) V Drug Eluting Stent in France
mehrAbbott's Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA
mehrAbbott and Genentech Announce Global, Integrated Research, Development and Commercialization Collaboration in Oncology
mehrAbbott to Initiate First Study to Evaluate XIENCE(TM) V Everolimus Eluting Coronary Stent System in Treatment of Women With Cardiovascular Disease
mehr
12Nächste